410070-90-5 Usage
Uses
Used in Pharmaceutical Industry:
6-Oxa-2-aza-spiro[3.4]octane is utilized as a key building block for the synthesis of biologically active compounds, contributing to the development of new pharmaceuticals with diverse therapeutic applications.
Used in Drug Development for Central Nervous System Disorders:
6-Oxa-2-aza-spiro[3.4]oct... is employed in the research and development of drugs intended for the treatment of central nervous system disorders, leveraging its unique structure to potentially address unmet medical needs in this therapeutic area.
Used in Synthesis of Biologically Active Compounds:
6-Oxa-2-aza-spiro[3.4]octane serves as a crucial intermediate in the synthesis of a variety of biologically active compounds, enhancing the discovery and creation of novel pharmaceutical agents with potential applications across different health conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 410070-90-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,1,0,0,7 and 0 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 410070-90:
(8*4)+(7*1)+(6*0)+(5*0)+(4*7)+(3*0)+(2*9)+(1*0)=85
85 % 10 = 5
So 410070-90-5 is a valid CAS Registry Number.
410070-90-5Relevant academic research and scientific papers
Development of a Large-Scale Route to an MCH1 Receptor Antagonist: Investigation of a Staudinger Ketene-Imine Cycloaddition in Batch and Flow Mode
Karlsson, Staffan,Bergman, Rolf,L?fberg, Christian,Moore, Peter R.,Pontén, Fritiof,Tholander, Joakim,S?rensen, Henrik
, p. 2067 - 2074 (2016/01/08)
A practical large-scale route to an MCH1 receptor antagonist is described. A Staudinger β-lactam synthesis of an imine and an in situ generated ketene was utilized as a key step for the preparation of a spiro-azetidine building block. The reaction was demonstrated in both batch and flow mode and a comparison of these techniques is described.
AZETIDINE DERIVATIVES FOR TREATMENT OF MELANIN RELATED DISORDERS
-
, (2013/03/26)
Disclosed herein are azetidinyl compounds of formula I, as described herein, pharmaceutical compositions comprising an azetidinyl compound, and a method of using an azetidinyl compound in the treatment or prophylaxis of a melanin- concentrating hormone related disease or condition.
